Azenta (AZTA) Q1 2024: SMS Ex-CNI Grows 9% as Automation and Repository Demand Outpace Market
Azenta’s Q1 showed resilient core growth in sample management and multi-omics, even as B Medical’s order timing weighed on overall results. Margin stability and cash flow discipline, coupled with a robust pipeline and new product launches, position the business for a back-half acceleration. Investors should watch for execution on B Medical contracts and the impact of automation and outsourcing trends on segment growth.
Summary
- Sample Management Strength: SMS ex-consumables delivered robust growth, fueled by automation and repository demand.
- Operational Discipline: Cost controls and positive free cash flow offset margin headwinds from B Medical timing.
- Back-Half Pipeline Criticality: B Medical conversion is pivotal for achieving full-year guidance and margin expansion.
Business Overview
Azenta is a life sciences solutions provider specializing in sample management (SMS, automation and storage for biological samples), multi-omics services (genomics, gene synthesis, next-generation sequencing), and B Medical (vaccine cold chain and sample logistics). The company generates revenue through a mix of service contracts, product sales, and long-term storage agreements, with a focus on enabling pharmaceutical, biotech, and academic customers to securely manage and analyze biological materials across the research and clinical development lifecycle.
Performance Analysis
Azenta’s Q1 headline decline masked underlying strength in its core businesses. Excluding B Medical, which saw revenue drop sharply due to order timing, the company posted organic growth of 2%. When also excluding the consumables and instruments (CNI) business, which has been a post-COVID headwind, organic growth reached 5%, consistent with Q4. The SMS segment grew 1% organically, but surged 9% ex-CNI, driven by a 37% jump in large automated stores and 6% growth in repository solutions. Multi-omics revenue grew 2% organically, with notable double-digit growth in China and gene synthesis, offsetting softness in North America and Sanger sequencing.
Margins reflected business mix and ongoing cost discipline. Company-wide non-GAAP gross margin compressed 190 basis points year-over-year to 43.5%, but excluding B Medical, margin was stable. Operating margin improved 160 basis points ex-B Medical, underpinned by expense management and cost reductions. Free cash flow was positive for the third consecutive quarter, at $15 million, highlighting improved working capital and operational focus even as reported EPS remained modest.
- SMS Automation Demand: Large automated stores revenue up 37%, signaling growing customer need for scalable, automated sample storage.
- Repository Services Expansion: Multi-year, multi-site repository contracts reinforce Azenta’s critical role in consolidating and managing complex sample collections.
- Multi-Omics Volume Leverage: Sequencing cost declines drove higher reaction volumes, offsetting pricing pressure and supporting stable margins.
While B Medical’s revenue shortfall was anticipated, its recovery and contract conversion remain key to achieving the full-year outlook. The business model’s recurring and project-based revenue mix, combined with accelerating automation and outsourcing adoption, supports above-market growth rates in core segments.
Executive Commentary
"We've embedded ourselves in a critical position in the center of a biological sample-based world that begins at discovery and goes all the way to the delivery of treatments. Our ability to source, manage, and store, and measure and interrogate samples, ultimately providing discovery-unlocking data, is paramount to all that is advancing this industry."
Steve Schwartz, President and Chief Executive Officer
"We ended the quarter in a very strong position with $1.1 billion in cash, cash equivalents, and marketable securities. Free cash flow was positive for the third quarter in a row at $15 million as we continue to focus on commercial, operational, and working capital management."
Herman Cuto, Chief Financial Officer
Strategic Positioning
1. Automation and Repository Scale-Up
Azenta’s investment in high-capacity, automated storage systems—exemplified by the BioARC Ultra launch—directly addresses customer demand for scalable, energy-efficient sample management. The company’s dual offering of on-site automation and off-site repository services positions it as a preferred partner for both outsourcing and internal workflow optimization.
2. Multi-Omics Elasticity and Margin Management
Technological advances have sharply reduced sequencing costs, driving up reaction volumes and lab efficiency. Azenta leverages this demand elasticity to maintain revenue and stable gross margins, even as pricing declines. The company’s consultative approach and capital investments in next-gen sequencing platforms help sustain customer relationships and defend profitability.
3. B Medical Pipeline and Geographic Diversification
B Medical’s vaccine cold chain and sample logistics pipeline remains robust, but revenue conversion hinges on funding flows and contract execution, especially in markets like the Democratic Republic of Congo (DRC). Expansion into whole blood sample retrieval services could transform B Medical from a product-centric to a hybrid services model, broadening Azenta’s recurring revenue base and global reach.
4. Channel and Sales Force Realignment
Dedicated sales teams for each segment and revitalized distribution channels have enabled Azenta to regain growth in challenging markets. The company’s “scientists selling to scientists” model in multi-omics is yielding traction, and the channel rebuild is supporting sequential improvements in CNI and broader customer engagement.
5. China Execution and Localized Growth
China remains a key growth engine, with double-digit expansion in multi-omics services and gene synthesis. Operational issues from prior periods are resolved, and the local team’s aggressive market approach is driving share gains despite macro and regulatory headwinds.
Key Considerations
Azenta’s Q1 highlights the importance of execution across its diversified platform, with automation, outsourcing, and international expansion offsetting near-term volatility in project-based revenue streams.
Key Considerations:
- Automation Tailwind: Accelerating demand for automated sample storage and repository solutions is driving SMS growth above market rates.
- Volume vs. Price in Multi-Omics: Sequencing price declines are offset by higher throughput and operational leverage, but sustained margin stability will require ongoing efficiency gains.
- B Medical Timing Sensitivity: Revenue recognition in B Medical is highly dependent on pipeline conversion and funding cycles, particularly in emerging markets.
- Channel Realignment Impact: The restructured sales organization is beginning to deliver results, but continued traction is needed for sustained recovery in CNI and broader segment growth.
- Cash Deployment Flexibility: With over $1 billion in liquidity and ongoing buybacks, Azenta retains significant capital allocation optionality for M&A or strategic investments.
Risks
Azenta’s reliance on project-based B Medical revenue introduces timing and funding risk, with potential for lumpiness if pipeline conversion is delayed. Continued pricing pressure in multi-omics could compress margins if volume gains do not keep pace, and macro or regulatory disruptions—especially in China and emerging markets—could impact growth trajectories. Execution on new product launches and sales channel realignment must deliver to sustain above-market growth rates.
Forward Outlook
For Q2, Azenta guided to:
- Mid- to high-single-digit organic revenue growth
- B Medical revenue expected to grow 25% sequentially
For full-year 2024, management maintained guidance:
- 5% to 8% organic revenue growth
- ~300 basis points of adjusted EBITDA margin expansion
- Non-GAAP EPS of $0.19 to $0.29
Management emphasized:
- The back half is weighted toward B Medical pipeline conversion, with core SMS and multi-omics revenue mix expected to remain balanced.
- Gross margin should improve toward the mid-40s as product mix normalizes and operational leverage increases.
Takeaways
Azenta’s core business momentum, driven by automation and repository demand, is offsetting near-term volatility in B Medical and CNI. Operational discipline and cash flow strength provide a buffer against margin headwinds. Execution on pipeline conversion and continued efficiency gains will be critical to achieving the full-year outlook.
- Core Growth Engines: SMS and multi-omics outperformed muted market trends, with automation and outsourcing as key secular drivers.
- B Medical Pipeline Execution: Timing of large contract conversion will determine the pace and magnitude of revenue and margin improvement in the second half.
- Efficiency and Capital Deployment: Sustained free cash flow and balance sheet strength enable continued investment and shareholder returns, but operational leverage must be maintained as pricing pressures persist.
Conclusion
Azenta’s Q1 results reinforce its positioning at the center of the sample-based life sciences value chain, with automation, repository, and multi-omics capabilities underpinning long-term growth. The path to full-year delivery hinges on B Medical execution and continued margin discipline, while product innovation and channel realignment offer additional upside.
Industry Read-Through
Azenta’s results highlight the accelerating trend toward automation and outsourcing in biological sample management, providing a read-through for peers in life sciences tools and services. The resilience of multi-omics demand despite pricing pressure signals that volume elasticity can support stable revenue in a deflationary cost environment—an important consideration for sequencing and genomics providers. The lumpiness and funding dependency in cold chain and sample logistics businesses is a cautionary signal for others exposed to large, project-based contracts, especially in emerging markets. Finally, operational discipline and channel realignment are proving essential for navigating post-COVID normalization across the sector.